Startup Deep Dive : Sascan Meditech — A million Singapore deal came from a chance lab visit

In February 2024, two visitors wandered into a small biophotonics lab in Thiruvananthapuram, spent an evening looking at a handheld cancer-screening device, and by the time they flew out that night had agreed to put in $2 million (₹16 crore) — more than thirteen times the ₹1.2 crore the company had booked in revenue that entire year. That company was Sascan Meditech, a Kerala medtech that had spent nine years building OralScan, a device it says can flag oral cancer at the point of care without a biopsy. For most of that decade, it survived on government grants and a single seed cheque, not on customers.

Sascan’s story is a useful corrective to the standard startup script. There is no unicorn valuation here, no headline monthly recurring revenue, and no clean growth curve. What there is: a laser physicist who spent 35 years in government labs before starting a company at an age when most founders are winding down, a near-shutdown after a mid-life relocation, a scientific partnership with an electronics giant that quietly fizzled, and a serendipitous hallway meeting that eventually did more for the company’s balance sheet than a decade of grant applications. This piece lays out what is actually known — and what is not — about how Sascan makes money, where it has struggled, and what its numbers say about its stage today.

Quick facts

What Sascan Meditech does

Sascan Meditech designs, manufactures and sells optical imaging devices that screen for cancers of the oral cavity and cervix without a biopsy. Its lead product, OralScan, is a handheld camera that shines light of four different wavelengths onto oral tissue and reads back patterns of autofluorescence and diffuse reflectance; a machine-learning model then flags suspicious lesions and suggests the best spot for a confirmatory biopsy, delivering a result in about five minutes. It is sold, leased or offered on a pay-per-scan basis to dental colleges, hospitals and screening camps, mostly in India, at a list price of ₹5.9 lakh per unit at launch with no recurring consumable cost. A second device, CerviScan, applies the same multimodal-imaging approach to cervical cancer screening and is still in clinical validation rather than commercial sale.

The origin

Subhash Narayanan is not a typical first-time founder. He holds a master’s in physics from Kerala University and a PhD in lasers from the Cochin University of Science and Technology, and from 1980 he worked in the Atmospheric Sciences Division of what is now the National Centre for Earth Science Studies in Thiruvananthapuram, using laser remote sensing to study vegetation and coral reefs. The idea for Sascan came out of that government-lab career, not out of it. During a visit to a Swedish laboratory that was using biophotonics — the interaction of light with biological tissue — to detect mouth and cervical cancer, Narayanan saw an application for techniques he already understood. In 2005 he pitched a similar project to the Indian government, won a grant, and ran the research through Trivandrum’s Regional Cancer Centre; the work later earned him the Indian Council of Medical Research’s Novartis Oration Award in 2010. He did not turn that research into a company until years later. Sascan Meditech was incorporated on 14 July 2015 in Bengaluru, roughly three years after he retired from government service, seeded by a Biotechnology Ignition Grant of about ₹50 lakh from the Biotechnology Industry Research Assistance Council (BIRAC). In the interim he had taken consulting roles at Forus Health, a Bengaluru health-tech firm, and at the aerospace company Vinvish in Trivandrum — work that, by his own account, kept the idea alive without yet being the company itself.

The struggle years

The first documented near-miss was self-inflicted. In 2018, family commitments pulled Narayanan back to Kerala, and Sascan’s research and development moved out of Bengaluru into the TIMed incubator at the Sree Chitra Tirunal Institute for Medical Sciences and Technology (SCTIMST) in Thiruvananthapuram — a relocation the company’s own technology partner, BIRAC, dates to April 2018. The move cost Sascan people: several early team members left, including a co-founder, Ruhi Agarwala. What the relocation bought back was institutional support from SCTIMST and the Kerala Startup Mission that the company did not have in Bengaluru, but for a period the founding team was smaller than when it started.

The second near-miss arrived with the pandemic. Unicorn India Ventures put in ₹2 crore in March 2020, just as India’s Covid-19 lockdowns began. Narayanan has said plainly that the cheque “helped us navigate the difficult Covid lockdown period without layoffs” — an admission that, without it, Sascan’s small team might not have stayed intact through 2020, the same year OralScan was finally readied for commercial launch in October.

The third setback was commercial rather than financial. OralScan’s early traction — CE marking, an Indian patent, a win at the 2021 Pharma and Medical Devices Grand Challenge, and donations of units to hospitals in Kerala — attracted interest from Panasonic, the Japanese electronics group, which was exploring an entry into medical devices and found Sascan through international exhibitions and a listing on the medtech marketplace MedZell. The collaboration never reached the scope either side wanted: Narayanan has said the project ran into time constraints and worked with sample sizes too small to meet the company’s own bar for evidence, even though the underlying technical work fed later product development. Underneath both the Panasonic episode and the years that followed sits a structural problem Narayanan has described without much softening: “there aren’t many institutions doing this in India, and many experts shy away from such work” — meaning the clinical publications needed to convince larger hospital chains to buy in simply were not being produced at scale, however good the device’s own trial results looked.

The turning point

The event that changed Sascan’s trajectory had nothing to do with a scheduled fundraise. On 27 February 2024, a delegation from Singapore-based Mercatus Capital, in the country as part of a Kerala State Industrial Development Corporation-organised visit, stopped at SCTIMST and wandered into Narayanan’s lab out of curiosity. He walked them through OralScan that afternoon; by evening he was presenting to the same visitors at their hotel; before they left Thiruvananthapuram that night, both sides had agreed to a deal. The result was a $2 million (₹16 crore) investment from Time Medical Digital Health and Imaging Ventures, a Visakhapatnam-based entity that had just completed a reverse merger in December 2023 with the BSE-listed shell Fischer Medical Ventures. Set against Sascan’s own numbers, the scale of that decision is stark: the company’s revenue for the fiscal year then ending was about ₹1.2 crore, meaning a single investment check was worth more than thirteen years of the company’s most recent annual revenue run rate. The money came earmarked for a specific pivot — building a manufacturing unit and an R&D facility in Singapore so that Sascan’s devices could carry a “Made in Singapore” label into export markets and sidestep the roughly 40% duty India levies on imported electronic components. It is the clearest evidence yet that outside capital, not government grants, will decide whether OralScan and CerviScan scale beyond India.

The money behind it

Sascan’s capital history is unusually grant-heavy for a company now nearly eleven years old, with equity investors arriving late and in only a handful of rounds:

• 2015 — Biotechnology Ignition Grant, BIRAC: approximately ₹50 lakh in non-dilutive government funding used to build the first OralScan prototype.
• 2017 — Elevate 100 seed backing: early seed-stage support under the Elevate 100 programme; amount undisclosed.
• March 2020 — Unicorn India Ventures: ₹2 crore in equity, the company’s first institutional venture round, credited by the founder with keeping the team intact through the Covid-19 lockdowns.
• 2021 — Startup India Grand Challenge: Sascan won the Pharma and Medical Devices Grand Challenge, run jointly by the Department of Pharmaceuticals, Startup India and Invest India, in the medical-devices category — prize and grant support rather than a priced equity round.
• 2023 — Department of Science and Technology: a further government grant, amount undisclosed, reported alongside Sascan’s inclusion in the Nasscom Deep Tech Emerge50 2023 cohort.
• 27 February 2024 — Time Medical Digital Health and Imaging Ventures / Fischer Medical Ventures: $2 million (₹16 crore), the company’s largest single round, earmarked for a Singapore manufacturing and R&D base.
• 17 July 2024 — Unicorn India Ventures partial exit: the 2020 investor sold part of its stake for a reported 6x return, while retaining a residual holding; the fund’s managing partner, Anil Joshi, described Narayanan as “a seasoned entrepreneur marrying technology and purpose.”
• 8 April 2025 — Fischer Medical Ventures (unit): a follow-on investment of ₹2 crore (₹20 million), announced on the BSE.

Adding only the disclosed equity cheques — Unicorn India Ventures’ ₹2 crore, the ₹16 crore Time Medical round and the ₹2 crore Fischer Medical follow-on — puts disclosed institutional funding at roughly ₹20 crore (about $2.1 million, converted at $1 ≈ ₹96.0) raised between 2020 and 2025, on top of undisclosed grant support from BIRAC, DST, Kerala Startup Mission and Startup India earlier in the company’s life. No round has come with a disclosed valuation.

How it makes money

Sascan is a hardware company first: its revenue comes from selling or renting a physical device, not from a recurring software or diagnostics-as-a-service fee. Academic research on the company’s commercialisation approach, published in the journal Science and Public Policy, documents four parallel routes to market rather than one:

• Direct sale to hospitals and dental clinics: a one-time purchase, sold through channel partners, at a list price of ₹5.9 lakh per unit at OralScan’s 2020 launch, with no ongoing consumable costs to the buyer.
• Lease model: a monthly rental arrangement for institutions unwilling or unable to commit capital expenditure upfront.
• Pay-per-use pricing: differentiated pricing tied to scan packages, aimed at lower-volume clinics and camps.
• Screening camps and awareness programmes: engagement with public-health stakeholders and NGOs that generates usage and clinical data even where it does not generate a device sale.

On the cost side, Sascan builds and assembles hardware in India — LED arrays, a monochrome camera, a tablet-based control unit and proprietary image-processing software — and has disclosed ISO 13485 certification, a CE mark, an Indian patent and a filed US patent, all costs that sit ahead of any given sale. The company has not published gross margin, take rate or unit economics for any of its business models, so this remains a genuine gap rather than a verified number. The part observers most often get wrong, in the founder’s own telling, is treating Sascan as a single-product company built around OralScan alone: he has framed the 2024 investment partly as a bet on a wider biophotonics platform that already includes CerviScan, photodynamic-therapy devices for oral lesions and diabetic foot ulcers, and consumer wellness products sold under the CureLite, CureLaze, CureWrap and VagusLite names — a diversified device portfolio he says “probably impressed” the Singapore-linked investors more than any single product’s numbers.

The numbers

Sascan is a small private company and files abridged financials with the Ministry of Corporate Affairs; only its two most recent fiscal years have verifiable, consistent revenue figures in public company-data trackers, and no source discloses profit or loss for any year. Rather than fill that gap with unverifiable estimates, the table below shows only what is confirmed:

• Paid-up capital: ₹9.28 lakh, against authorised capital of ₹25 lakh, as of the company’s most recent MCA filing.
• Open charges/borrowings: approximately ₹5.2 crore recorded against the company as of the same filing.
• FY23 and earlier revenue: not independently verifiable; different data aggregators show inconsistent figures for these years and are excluded here rather than reported.

Where the money comes from

Sascan’s revenue base today is narrower, and more public-sector-oriented, than its media coverage might suggest:

• Product mix: OralScan is the only commercially sold product; CerviScan remains in Phase-3 clinical validation, having shown 100% sensitivity and 93% specificity in a 109-patient pilot at Kasturba Medical College, Manipal, but is not yet a revenue line.
• Named deployment sites: peer-reviewed case documentation lists OralScan in use at the Government Dental College, Thiruvananthapuram; JSS Dental College and Hospital, Mysuru; the Institute of Medical Sciences and Sum Hospital, Odisha; Sree Balaji Dental College and Hospital, Chennai; and Dayanand Sagar Dental College, Bengaluru — a footprint weighted toward public and academic dental institutions rather than large private hospital chains.
• Channel split: alongside direct hospital sales, a meaningful share of usage comes through screening camps and public-health outreach rather than private capital-expenditure budgets, consistent with the company’s own “bottom of the pyramid” framing of its mission.
• Geography: commercial revenue to date is overwhelmingly domestic; the 2024 investment’s stated purpose — a Singapore manufacturing and R&D base — signals that export revenue is a 2024-onward ambition rather than a current, disclosed contributor.
• The surprise: for a company with a hardware product and a headline VC-style funding round, government grants (BIRAC, DST, Startup India, Kerala Startup Mission) funded more of Sascan’s first eight years than private equity did — institutional capital only became the larger story from 2020, and the largest single cheque only arrived in 2024.

The risks

• Thin institutional evidence base: the founder has said outright that “there aren’t many institutions doing this in India, and many experts shy away from such work,” meaning the multi-centre published clinical evidence that large hospital networks require before procurement is still limited relative to the device’s decade-long development. Until that evidence base widens, Sascan’s addressable buyer base skews toward public dental colleges and camps rather than premium private chains.
• Partnership execution risk: even credible corporate interest has not reliably converted into scale. The Panasonic collaboration, which Sascan itself has discussed publicly, did not reach its intended scope because of time constraints and sample sizes the company judged too small — a reminder that named-brand interest is not the same as a distribution deal.
• Capital-to-revenue mismatch: FY25 revenue of ₹1.52 crore sits against roughly ₹20 crore in disclosed equity funding raised since 2020, most of it in the single 2024 round earmarked for a new Singapore manufacturing and R&D base. That gap is not unusual for a pre-scale medtech hardware company, but it does mean the near-term test for Sascan is whether the Singapore build-out and export push can lift revenue by a multiple of where it stands today, not by the incremental 25–26% year-on-year growth seen domestically in FY24–FY25.

The takeaway

Sascan Meditech’s most transferable lesson is not about product design or clinical accuracy; it is about survival cadence. A deep-tech, hardware-heavy medtech idea born out of government-lab research took the better part of two decades — from a 2005 research grant to a 2024 growth-stage cheque — to find capital that matched its ambitions, and it did so by staying alive on non-dilutive grants and one modest seed round through a relocation, a pandemic and a partnership that fizzled, rather than by hitting a scheduled fundraising milestone. The Singapore deal itself was not sourced through a pitch deck or a banker; it came from a chance lab visit that only worked because the underlying regulatory and clinical groundwork — CE marking, patents, multi-hospital trials — was already done when the opportunity walked in. For founders in capital-intensive, evidence-heavy sectors, the operating lesson is less “raise fast” and more “stay fundable long enough that the right buyer’s arrival, whenever it comes, is a formality rather than a scramble.”

Frequently asked questions

What does Sascan Meditech make?

Sascan makes handheld optical-imaging devices for early cancer screening. Its commercial product, OralScan, screens for oral cancer using tissue fluorescence and reflectance imaging with machine-learning-assisted lesion detection. A second device, CerviScan, targets cervical cancer screening and is still in clinical validation rather than commercial sale.

Who founded Sascan Meditech and when?

Dr Subhash Narayanan, a laser physicist who previously worked at the National Centre for Earth Science Studies in Thiruvananthapuram, incorporated Sascan Meditech Private Limited on 14 July 2015 in Bengaluru, with Usha Subhash as co-founder.

How much funding has Sascan Meditech raised?

Disclosed equity funding totals roughly ₹20 crore (about $2.1 million) across three rounds between March 2020 and April 2025 — from Unicorn India Ventures, Time Medical Digital Health and Imaging Ventures, and Fischer Medical Ventures — on top of undisclosed grants from BIRAC, the Department of Science and Technology, Kerala Startup Mission and Startup India earlier in the company’s life. No valuation has been publicly disclosed for any round.

Is Sascan Meditech profitable?

That is not publicly known. Sascan reported revenue of ₹1.52 crore in FY25, up from ₹1.2 crore in FY24, but has not disclosed profit or loss figures for either year in any public filing summary.

Is OralScan available outside India?

OralScan carries a CE mark and Sascan has filed a US patent, but the company’s disclosed commercial deployments to date are within India. A 2024 investment from Time Medical Digital Health and Imaging Ventures is earmarked specifically to build a manufacturing and R&D base in Singapore aimed at export markets, making international commercial sales a stated plan rather than a currently disclosed revenue source.

Sources

Figures are as of September 2026. Currency converted at $1 ≈ ₹96.0 as of 18 September 2026 (Trading Economics).

• Inc42, “Sascan Meditech — Funding & Revenue” company profile, 2026
• Inc42, “Sascan Meditech Funding” round-by-round page, 2026
• Inc42, “Unicorn India Ventures Partially Exits From Sascan Meditech With 6X Returns,” 17 July 2024
• MediaBrief, “Unicorn India Ventures announces partial exit from Sascan Meditech after Rs 2 crore investment,” July 2024
• Kerala Technology, “Sascan lands a Singapore surprise,” by Hari Kumar, 6 August 2024
• MarketScreener, “Fischer Medical Ventures Unit Invests Additional INR20 Million in Sascan Meditech,” 8 April 2025
• Sascan Meditech Pvt Ltd, “About Us,” company website, accessed September 2026
• BioSpectrum India, “Sascan Meditech launches hand held oral cancer screening tool,” October 2020
• Department of Science and Technology, Government of India, “OralScan, a handy oral cancer screening tool launched,” October 2020
• BIRAC 3i Portal, OralScan product detail page, accessed September 2026
• Science and Public Policy (Oxford Academic), “Conceptualising inclusive innovation: evidence from AI-based MedTech for cancer detection in India,” 2026
• TheCompanyCheck, “Sascan Meditech Private Limited — FY 2025 Insights,” accessed September 2026
• Tofler, “Sascan Meditech Private Limited” company financial record, accessed September 2026
• World Cancer Research Fund, “Mouth and oral cancer statistics” (GLOBOCAN 2022 data), accessed September 2026
• ScienceDirect / PMC, “Cervical cancer burden in India: A descriptive epidemiological study and policy insights” (GLOBOCAN 2022; NFHS-5, 2019–21), 2026
• ThePrint, “Cervical cancer falling, breast and oral cancers rising: ICMR analysis shows a split in India’s trend,” 2026

Found an error? Write to us and we’ll correct it in the open, dated, on the piece.